MA17366

Hepatitis C Virus Core Antigen Monoclonal Antibody (D95B), Invitrogen™

Manufacturer: Thermo Scientific

Select a Size

Pack Size SKU Availability Price
Each of 1 MA17366-Each-of-1 In Stock ₹ 50,507.50

MA17366 - Each of 1

₹ 50,507.50

In Stock

Quantity

1

Base Price: ₹ 50,507.50

GST (18%): ₹ 9,091.35

Total Price: ₹ 59,598.85

Antigen

Hepatitis C Virus Core Antigen

Classification

Monoclonal

Concentration

0.1 mg/mL

Formulation

PBS with 0.1% sodium azide; pH 7.2

Host Species

Mouse

Purification Method

Protein A

Regulatory Status

RUO

Target Species

Virus

Product Type

Antibody

Isotype

IgG1

Applications

ELISA, Immunohistochemistry, Western Blot

Clone

D95B

Conjugate

Unconjugated

Gene Alias

HCV core; HCVgp1; HepC; HepC core; polyprotein

Immunogen

Viral core protein.

Quantity

100 μg

Primary or Secondary

Primary

Content And Storage

4° C

Form

Liquid

Related Products

Img

Thermo Scientific

MA17356

--

Img

Thermo Scientific

MA17367

--

Img

Thermo Scientific

MA17343

--

Img

Thermo Scientific

MA17368

--

Img

Thermo Scientific

MA17371

--

Img

Thermo Scientific

MA17292

--

Img

Thermo Scientific

MA1080

--

Img

Thermo Scientific

MA17363

--

Description

  • The MA1-7366 antibody reacts with Hepatitis C virus (genotypes 1a,1b, and 2a) core capture/probe in viral and infected tissue samples
  • MA1-7366 has been successfully used in ELISA, Immunofluorescence, Western blot and Immunohistochemical applications
  • The MA1-7366 antibody was raised against the HCV Viral core protein
  • The epitope of MA1-7366 has been mapped amino acids 33-38 of HCV
  • HCV is a positive, single-stranded RNA virus in the Flaviviridae family
  • The genome is approximately 10,000 nucleotides and encodes a single polyprotein of about 3,000 amino acids
  • The polyprotein is processed by host cell and viral proteases into three major structural proteins and several non-structural protein necessary for viral replication
  • Several different genotypes of HCV with slightly different genomic sequences have since been identified that correlate with differences in response to treatment with interferon alpha.